Galafold 123 MG
Ended Awarded
- Contract number
- 36C24526N0306
- Awardee
-
Amicus Therapeutics US, LLC UEI KLJFGENKMD89
- Awarding agency
-
Veterans Integrated Service Network 5
Veterans Health Administration, Department of Veterans Affairs
- Obligated
- $22,840
Award facts
- Contract value 100% obligated
- $22,839.61 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- Contracting staff
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
- Place of performance
- Philadelphia, PA 19104, USA
Award details come from SAM.gov/FPDS.
About this award
The Department of Veterans Affairs, Veterans Integrated Service Network 5 (Mid-Atlantic region), awarded a delivery order valued at $22,839.61 to Amicus Therapeutics US, LLC for the supply of Galafold 123 mg, an FDA-approved enzyme replacement therapy for the treatment of Fabry disease. This firm fixed-price delivery order, awarded on February 8, 2026, with an ultimate completion date of February 10, 2026, represents a continuation of the vendor's extensive supply relationship with the VA. The contract includes no set-aside designation and specifies performance at a Philadelphia, PA location.
This delivery order is issued under Amicus Therapeutics US, LLC's multiple-award Federal Supply Schedule contract (36F79724D0185) for Pharmaceuticals and Drugs (FSS-61-IB), valued at $13.0M and effective through August 31, 2029. The parent FSS contract, awarded on September 1, 2024, enables various Veterans Integrated Service Networks across the country to procure specialized pharmaceutical products critical to veteran healthcare. Amicus Therapeutics US, LLC has historically fulfilled over 150 delivery orders under this vehicle since March 2021, serving multiple VA regions and maintaining consistent direct performance as the prime contractor with no subcontractor involvement, reflecting its established role as a key supplier of rare disease treatments within the federal healthcare system.
Quick answers
Who was awarded contract 36C24526N0306?
36C24526N0306 was awarded to Amicus Therapeutics US, LLC by Veterans Integrated Service Network 5 (Veterans Health Administration) on February 8, 2026.
How much is contract 36C24526N0306 worth?
The government has obligated $22,840 on 36C24526N0306.
Is contract 36C24526N0306 an order under another contract?
Yes. 36C24526N0306 is a delivery order under 36F79724D0185, a federal supply schedule, on Pharmaceuticals and Drugs (FSS-61-IB).
Was contract 36C24526N0306 competed?
The extent of competition for 36C24526N0306 was full and open competition. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award